The MEK and MET Inhibition in Colorectal Cancer trial (MErCuRIC1) was a phase I clinical trial aiming to test the combination of crizotinib with a MEK inhibitor, either binimetinib or PD-0325901, in CRC patients with either a KRAS mutation or aberrant c-MET activation. The gene discussed is MET; the disease is colorectal cancer.